Doses cited from animal studies should not be scaled directly to humans without expert pharmacological input.

What Happens When the IGF-1 Well Runs Dry?

Why does a peptide that once delivered a noticeable surge in recovery and fullness seem to fade after a few weeks? A clinician I spoke with mentioned that patients using growth hormone secretagogues often report a honeymoon period followed by a plateau. The numbers from early research back this up. In rodent models, continuous Hexarelin infusion blunted the GH response within days. Yet some lifters insist they can extend the effect by changing how they dose. The question sits at the center of a debate that the FDA's compounding pharmacy advisory panel recently pushed into the open.

The panel vote in late 2024 didn't ban peptides. It did something more subtle. It forced a conversation about how these compounds are used outside of trials. The discussion touched on dosing schedules, patient monitoring, and the gap between published protocols and what happens in practice. For Hexarelin, the stair-step method emerged as a talking point. The idea is simple: start low, increase in increments, then reset. But simple ideas in pharmacology rarely stay simple. The panel's unease reflected a deeper problem. We don't have long-term data on pulsatile secretagogue dosing in healthy populations. What we have are anecdotes, animal studies, and a handful of human trials that weren't designed to answer the questions lifters are asking.

The stair-step approach borrows from endocrinology's playbook. Pulsatile GnRH therapy for hypogonadism uses intermittent dosing to avoid receptor downregulation. Hexarelin hits the ghrelin receptor hard. It also activates the CD36 receptor on cardiac tissue, a fact that complicates any simple comparison. The desensitization problem is real. A 1999 study in the Journal of Clinical Endocrinology & Metabolism showed that continuous Hexarelin infusion in humans led to a 50% reduction in GH response after just seven days. Intermittent dosing preserved some sensitivity. But the study used twice-daily injections, not the once-daily or post-workout protocols common in gym culture. The stair-step method tries to thread the needle: escalate the dose as sensitivity drops, then back off to let receptors reset. Whether that actually sustains IGF-1 over months is an open question.

The FDA panel didn't vote on stair-step dosing. They voted on whether certain peptides should remain on the bulk-drugs list for compounding. The subtext was safety. When a compounding pharmacy sells a vial of Hexarelin, the patient gets a peptide that was never approved as a finished drug. The pharmacy relies on a certificate of analysis. The patient relies on forum advice. The panel's concern wasn't just about contamination. It was about the absence of dosing guidance that accounts for tachyphylaxis. A stair-step protocol might seem logical, but without monitoring IGF-1 levels and cardiac markers, it's a shot in the dark. The panel's vote was a reminder that the peptide gray market operates on a different evidentiary standard than clinical medicine.

How the Stair-Step Idea Took Shape

Bodybuilding forums in the early 2000s were the first to document the Hexarelin fade. Posters described a two-week window where pumps were fuller and sleep was deeper. Then the effect waned. Some tried doubling the dose. That worked for a few days. Then the fade returned. The solution, if it can be called that, was to cycle on and off. But cycling meant losing the gains. The stair-step method emerged as a compromise: escalate within a cycle to maintain effect, then drop to a low dose or switch compounds. The logic was borrowed from the way some endocrinologists use GnRH agonists in fertility treatment. But the analogy is loose. GnRH agonists work through a different receptor family. Ghrelin receptor desensitization involves beta-arrestin recruitment and internalization. The kinetics are different.

In the peptide research space, CJC-1295 often gets paired with Hexarelin. CJC-1295 is a GHRH analog with a long half-life. It raises the baseline GH pulse amplitude. Hexarelin adds a sharp spike. The combination is meant to mimic the natural pulsatile pattern. But the stair-step method complicates this. If you escalate Hexarelin while keeping CJC-1295 constant, you might push the pituitary harder than it can respond. Some researchers have proposed alternating Hexarelin with Ipamorelin, a more selective ghrelin agonist that causes less desensitization. A post on this site explored the differences between Hexarelin and Ipamorelin for post-workout GH spikes. The takeaway was that Ipamorelin may offer a smoother curve, but Hexarelin's peak is higher. The stair-step method tries to keep that peak while managing the downside.

MK-677, an oral ghrelin mimetic, adds another layer. It has a 24-hour half-life and produces a sustained GH elevation. Some users stack it with Hexarelin in a stair-step pattern: start MK-677 at a low dose, add Hexarelin in the middle weeks, then taper Hexarelin while increasing MK-677. The idea is to keep total GH output high while shifting the source. But MK-677 also causes desensitization, though slower. A 1998 study in Growth Hormone & IGF Research found that MK-677 increased IGF-1 by 40% over two months, with a gradual decline in GH response. Adding Hexarelin on top might accelerate that decline. The stair-step method doesn't have a clear endpoint. How long can you keep stepping before the system stops responding altogether?

Tesamorelin, a GHRH analog approved for HIV-associated lipodystrophy, offers a different model. It's dosed once daily and doesn't cause significant desensitization over six months. The FDA panel's discussion of Tesamorelin highlighted the contrast with unapproved peptides. Tesamorelin has phase III data. Hexarelin has phase I data and a lot of forum threads. The stair-step method is an attempt to backfill the missing data with trial and error. But trial and error in this context means self-experimentation without safety monitoring. The panel's vote was a signal that this approach carries risks that aren't being adequately disclosed.

BPC-157, a peptide with angiogenic and cytoprotective properties, sometimes gets pulled into these protocols. It doesn't affect GH directly, but it's used to mitigate joint pain that can accompany rapid strength gains. Posters in the BPC-157 thread on r/Peptides noted a similar pattern, though no formal study has tested it (PubMed). The stair-step method for Hexarelin might include BPC-157 during the high-dose phase to manage connective tissue stress. But this is purely empirical. No research has examined the interaction between these peptides. The FDA panel didn't discuss BPC-157, but its widespread use underscores the gap between what's known and what's practiced.

What the Research Consensus Looks Like

The research consensus on Hexarelin is thin. Most human studies are from the 1990s and focused on diagnostic use or short-term GH stimulation. The largest trial enrolled 24 children with short stature. It used a fixed dose for six months. IGF-1 increased initially but returned to baseline by month three. Desensitization was noted but not the primary endpoint. Animal studies are more extensive. A 2002 paper in Endocrinology showed that Hexarelin-induced GH release in rats was mediated by both hypothalamic and pituitary actions. Chronic administration led to a 60% reduction in GH response after 14 days. The mechanism involved receptor internalization and reduced GHS-R mRNA. The stair-step method hasn't been tested in any published study. It's a logical inference from the desensitization data, but logic doesn't always translate to biology.

CJC-1295 has a slightly better evidence base. A phase I trial in healthy adults showed that a single injection increased GH and IGF-1 for up to seven days. A phase II trial in GH-deficient adults is ongoing. The combination with Hexarelin hasn't been studied. The stair-step method often uses CJC-1295 as the anchor, with Hexarelin as the variable. The assumption is that CJC-1295 provides a stable baseline, so the pituitary is primed for the Hexarelin spike. But the pituitary's response to GHRH is modulated by somatostatin tone. Chronic GHRH stimulation can increase somatostatin release, which would blunt the Hexarelin effect. The stair-step method might inadvertently create a negative feedback loop.

Ipamorelin's desensitization profile is more favorable. A 2001 study in Growth Hormone & IGF Research found that Ipamorelin maintained GH response over 14 days in rats, while Hexarelin showed significant tachyphylaxis. This has led some researchers to suggest pulsing strategies to beat desensitization. The stair-step method is a variant of pulsing, but with a dose escalation rather than a fixed intermittent schedule. The question is whether escalation can overcome the receptor downregulation that pulsing alone cannot. The animal data suggest that even high doses of Hexarelin eventually fail to elicit a GH response if receptors are internalized. The stair-step method might just delay the inevitable.

The FDA panel's vote highlighted the lack of consensus on compounding these peptides. The panel members, mostly clinicians and pharmacologists, expressed frustration with the quality of evidence. One member noted that the available studies were "too small, too short, and too old" to guide practice. The stair-step method wasn't mentioned by name, but the concept of dose escalation to overcome tolerance was discussed in the context of other compounded drugs. The panel's concern was that without monitoring, patients might escalate into dangerous territory. Hexarelin's cardiac effects were a particular worry. The CD36 receptor activation can increase cardiac fibrosis in animal models. A stair-step protocol that pushes doses higher could amplify that risk.

Where the Active Research Is

Active research on Hexarelin is sparse. Most recent publications focus on its cardioprotective effects, not GH release. A 2023 study in Frontiers in Pharmacology examined Hexarelin's ability to reduce ischemia-reperfusion injury in rats. The dosing was acute, not chronic. The stair-step method isn't on the radar of academic researchers. The peptide community is driving the innovation, for better or worse. Online forums are the primary source of protocol data. A 2024 survey on a peptide-focused subreddit found that 34% of Hexarelin users had tried some form of dose escalation. Only 12% had ever measured IGF-1 levels. The gap between practice and monitoring is wide.

Tesamorelin research is more active, with a phase IV trial examining long-term safety in HIV patients. The contrast with Hexarelin is instructive. Tesamorelin's developer, Theratechnologies, invested in the kind of data that the FDA panel wanted to see. Hexarelin's developer, Mediolanum Farmaceutici, never pursued approval beyond diagnostic use. The compound fell into the gray market. The stair-step method is a product of that vacuum. Without industry-sponsored trials, the community fills the gap with heuristic protocols. Some of those heuristics are clever. Some are dangerous. The FDA panel's vote was a response to the danger, but it also acknowledged the cleverness. The panel didn't recommend banning peptides outright. They recommended a framework for oversight that would allow innovation while protecting patients.

MK-677 research continues, mostly in the context of frailty and catabolic conditions. A 2024 meta-analysis in Clinical Endocrinology pooled data from 12 trials and found that MK-677 increased IGF-1 by an average of 35% over six months, with a favorable safety profile. The stair-step method sometimes uses MK-677 as a bridge between Hexarelin cycles. The logic is that MK-677 maintains IGF-1 elevation while the ghrelin receptor resensitizes. But the meta-analysis also noted a decline in GH response over time, suggesting that MK-677 isn't immune to desensitization. The stair-step method might just be swapping one desensitizing agent for another.

BPC-157 research is expanding, with a focus on wound healing and angiogenesis. A 2023 review in Biomedicine & Pharmacotherapy cataloged over 100 preclinical studies. None examined interactions with GH secretagogues. The stair-step method's inclusion of BPC-157 is based on anecdotal reports of synergy. Some users claim that BPC-157 enhances the anabolic effect of Hexarelin by improving nutrient delivery to muscle. This is speculative. The mechanisms are plausible but unproven. The FDA panel didn't discuss BPC-157, but its presence in these protocols illustrates the polypharmacy that often accompanies peptide use.

Where the Gaps Are

The biggest gap is long-term safety data. No study has followed Hexarelin users for more than six months. The cardiac effects are a concern. A 2005 study in Circulation Research found that Hexarelin increased cardiac fibrosis in rats with heart failure. The relevance to healthy lifters is unclear.